American Well (AMWL) Q2 2026 Earnings Call Transcript

American Well (AMWL) reported Q2 2026 revenue of $52 million, down 26.6% year over year, with subscription revenue of $25.7 million and AMG revenue of $24.4 million. Adjusted EBITDA loss was $1.15 million and net loss was $9.6 million. Full-year guidance was narrowed to $200-$205 million revenue and improved adjusted EBITDA loss to $9-$7 million. The Defense Health Agency issued an intent to award a sole-source contract.

Original reporting
Published Aug 12, 2026, 2:30 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 12, 2026, 3:09 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
American Well (AMWL) Q2 2026 Earnings Call Transcript — source image
Decision brief

The 30-second read

$AMWLBullishMed
01

Why it matters

Traders can update expectations for 2026 revenue and profitability trajectory based on raised guidance, while monitoring whether the sole-source intent converts into a binding contract and how churn affects subscription growth.

02

Market read

Raised 2026 revenue and adjusted EBITDA loss outlook, plus a DHA sole-source intent, are the main near-term drivers; Q3 loss guidance and churn temper the upside.

03

What to watch

Q2 revenue decline is attributed to churn, and Q3 adjusted EBITDA guidance still implies losses due to internal project completion costs, which could cap upside despite raised full-year targets.

Relevance 8/10Novelty 7/10Timing: post-earnings call, before Q3 results

Background

American Well’s call discusses Q2 2026 performance, transformation toward an AI-powered care infrastructure platform, and a government procurement intent tied to its platform.

Company-level read

Ticker impact

$AMWLBullishMedium confidence
Context

American Well reported Q2 results and raised full-year revenue to $200M-$205M, plus raised adjusted EBITDA loss guidance to $9M-$7M.

Expected impact

Bias modestly positive for AMWL, with volatility around contract confirmation and the next-quarter loss profile.

Evidence & confidence

The article contains fresh, decision-relevant guidance numbers and a new government procurement intent, but it also flags temporary higher costs in Q3 and ongoing subscription churn.

Market effects

Reinforces demand for telehealth infrastructure and AI-enabled care platforms in government healthcare procurement, potentially supporting the broader digital health narrative.

Primarily US government healthcare contracting signal; limited direct regional spillover beyond US healthcare IT.

Low global relevance; the catalyst is US Defense Health Agency procurement and US financial guidance.

Counterpoint

The DHA notice is only an intent to award, so the market may over-discount execution risk and timing uncertainty until a final contract is signed.

Key entities

  • American Well

    AMWL, reported Q2 2026 results and issued raised full-year guidance plus a Defense Health Agency sole-source intent update.

  • Defense Health Agency

    DHA issued an intent to award a sole-source contract directly to American Well for a platform transition.

  • Oracle Health

    Named as one of the proprietary providers included in the DHA transition described in the article.

  • Philips

    Named as one of the proprietary providers included in the DHA transition described in the article.

Related articles

$AMWLMed

American Well Corp (AMWL) Q3 2026 Earnings Call Highlights: Revenue Beat, Raised Guidance

American Well Corp (AMWL) reported Q3 2026 revenue of $49M, down 12.9% YoY. Subscription revenue fell 22.5% due to churn. Platform visits dropped 30.5% YoY. The VA letter of intent is non-binding, and the DHA contract conversion is pending. CEO Dr. Ido Schoenberg expressed optimism about negotiations and potential growth opportunities. The company expects Q4 adjusted EBITDA breakeven and raised guidance.

$AMWLMedAI 8/10

What American Well (AMWL) Said on Its Q3 Earnings Call

Amwell (AMWL) reported Q3 earnings with virtual primary care visits up 41% YoY, but total platform visits down 30.5%. Gross profit was $26M with a 53% margin. Q4 revenue is forecasted at $48M-$50M, with adjusted EBITDA expected to break even or turn positive. The company raised its full-year 2026 outlook, now expecting revenue of $204M-$206M and a reduced adjusted EBITDA loss. Amwell also discussed potential government contracts, including a nonbinding letter of intent from the VA.

$AMWLHigh

American Well Corp (AMWL): AMWELL® ANNOUNCES RESULTS FOR THE third QUARTER 2026

American Well Corp (AMWL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 AMWELL® ANNOUNCES RESULTS FOR THE third QUARTER 2026 BOSTON, November 3 , 2026 –Amwell ® (NYSE: AMWL), a leading provider of a comprehensive SaaS-based technology-enabled healthcare platform, today announced financial results for the third quarter ended September 30,

$AMWLMed

American Well Corp (AMWL): AMWELL® ANNOUNCES RESULTS FOR THE Second QUARTER 2026

American Well Corp (AMWL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 AMWELL® ANNOUNCES RESULTS FOR THE Second QUARTER 2026 BOSTON, August 4 , 2026 –Amwell ® (NYSE: AMWL), a leading provider of a comprehensive SaaS-based technology-enabled healthcare platform, today announced financial results for the second quarter ended June 30, 2026